American Journal of Epidemiology Advance Access originally published online on September 22, 2007
American Journal of Epidemiology 2008 167(1):90-95; doi:10.1093/aje/kwm260
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL CONTRIBUTIONS |
Peripheral Inflammatory Biomarkers and Risk of Parkinson's Disease
1 Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC
2 Department of Nutrition, Harvard School of Public Health, Boston, MA
3 Department of Neurology, Massachusetts General Hospital, Boston, MA
4 Department of Epidemiology, Harvard School of Public Health, Boston, MA
5 Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Correspondence to Dr. Alberto Ascherio, Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115 (e-mail: aascheri{at}hsph.harvard.edu).
Received for publication April 13, 2007. Accepted for publication August 14, 2007.
Experimental and postmortem evidence indicates a role of neuroinflammation in the pathogenesis of Parkinson's disease. The authors prospectively examined whether plasma concentrations of inflammatory biomarkers assessed before Parkinson's disease diagnosis were predictive of future risk of the disease in a nested case-control study in the United States (1993–2002), including 84 incident cases and 165 matched controls. Blood was collected from patients on average 4.3 years before the diagnosis. After adjustment for potential confounders, higher level of interleukin-6 was associated with a greater risk of Parkinson's disease. Compared with the lowest quintile, the odds ratios were 1.5 for the second, 1.6 for the third, 2.7 for the fourth, and 3.4 for the fifth quintiles (p for trend = 0.03). In contrast, concentrations of other inflammatory biomarkers including C-reactive protein, fibrinogen, and tumor necrosis factor-
receptors were not related to the risk. These data suggest that men with high plasma concentrations of interleukin-6 have an increased risk of developing Parkinson's disease. However, this finding should be interpreted with caution because of the small sample size and the lack of associations with other biomarkers of inflammation.
biological markers; C-reactive protein; inflammation; interleukin-6; odds ratio; Parkinson disease; tumor necrosis factor-
Abbreviations: IL, interleukin; TNF, tumor necrosis factor
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Rugbjerg, S. Friis, B. Ritz, E. S. Schernhammer, L. Korbo, and J. H. Olsen Autoimmune disease and risk for Parkinson disease: A population-based case-control study Neurology, November 3, 2009; 73(18): 1462 - 1468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Marek and D. Jennings Can we image premotor Parkinson disease? Neurology, February 17, 2009; 72(7_Supplement_2): S21 - S26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Frank-Cannon, T. Tran, K. A. Ruhn, T. N. Martinez, J. Hong, M. Marvin, M. Hartley, I. Trevino, D. E. O'Brien, B. Casey, et al. Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration J. Neurosci., October 22, 2008; 28(43): 10825 - 10834. [Abstract] [Full Text] [PDF]
|
|